CN101631782A - 制备开环紫杉烷类的方法 - Google Patents
制备开环紫杉烷类的方法 Download PDFInfo
- Publication number
- CN101631782A CN101631782A CN200780046778A CN200780046778A CN101631782A CN 101631782 A CN101631782 A CN 101631782A CN 200780046778 A CN200780046778 A CN 200780046778A CN 200780046778 A CN200780046778 A CN 200780046778A CN 101631782 A CN101631782 A CN 101631782A
- Authority
- CN
- China
- Prior art keywords
- formula
- straight
- compound
- branched
- oxazolidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Epoxy Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明公开了从10-去乙酰基浆果赤霉素III和(4S,5R)-N-Boc-2-(2,4-二甲氧基苯基)-4-异丁基-1-噁唑烷-5-甲酸开始制备开环紫杉烷类的方法。
Description
本发明公开了从10-去乙酰基浆果赤霉素和(4S,5R)-N-Boc-2-(2,4-二甲氧基苯基)-4-异丁基-1-噁唑烷-5-甲酸开始制备开环紫杉烷类的方法。
发明背景
在WO 96/03394中以及随后由Appendino等人(Tetrahedr.Lett.1995,36(18),3233-3236)所公开的化合物IDN5390(I)是目前作为抗肿瘤药物进行临床试验的紫杉烷衍生物。
选择IDN 5390是由于其抗血管生成的特性,该特性在内皮和卵巢肿瘤细胞的体外和体内试验研究中均得到证实。对于不同的肿瘤组织型,例如卵巢、结肠和乳腺肿瘤,在口服给药后证实该化合物有效。还证实IDN 5390对瘤转移模型以及对紫杉醇治疗敏感性差的肿瘤有效。其作用机制的一项特性是其活性不依赖于III类β-微管蛋白的表达状态,而后者是近来在临床水平上发现的一种重要的对紫杉醇的抵抗机制(Ferlini等人,Cancer Res.65,(6),2397,2005)。低剂量施用的IDN 5390显示出抗血管生成的特性(Taraboletti等人,Anti-Cancer Drugs 14,255,2003)。
根据现有技术,该化合物的合成途径,如US 5,756,776和Appendino等人(Tetrahedr.Lett.1995,36(18),3233-3236;Tetrahedr.Lett.1997,38(24),4273-4276)所公开的方法,通常包括在7-和9-位被保护为硅烷基醚的开环浆果赤霉素与被保护为式(II)的噁唑烷的Norstatine残基进行的酯化反应。
被保护的开环浆果赤霉素通过以下途径获得:10-去乙酰基浆果赤霉素III用醋酸铜在甲醇中氧化,然后用氢化物断裂还原(fragmentativereduction),而对7-和9-位的保护通常使用三乙基硅烷基氯化物。将所得产物与按照WO 01/02407中所公开的方法制备的(4S,5R)-N-Boc-2-(2,4-二甲氧基苯基)-4-异丁基-1-噁唑烷-5-甲酸在碳二亚胺的存在下进行酯化。
所述方法提供了30-40%的平均总产率,然而一些缺点使其在工业化规模应用中存在问题。首先,10-去乙酰基浆果赤霉素III与氧化铜的氧化反应容易因过度氧化而导致13-氧代衍生物的形成,从而显著降低了转化产率。此外,被保护为硅烷基醚或酯的保护反应很难控制,因为13位也发生反应,得到无用的7,9,13-三保护的开环浆果赤霉素。
最后,如本领域技术人员已知的,被保护的开环浆果赤霉素与式II的Norstatin的缩合比带有完整C环的浆果赤霉素更难进行,因此需要更高的反应温度和更长的反应时间。
氧化反应的缺点和保护的区域选择性以及与式II的链进行缩合的难度,促使申请人开发了新的半合成方法,这是本发明的目的。
发明内容
现已发现,上述合成问题可以通过以下的合成流程来解决,其不仅可以有利地应用于上述式(I)化合物,而且也可普遍地用于式(III)的紫杉烷类化合物
其中
R1是氢或者直链或支链的C1-C4烷基、直链或支链的C1-C4烷氧基、F、Cl、Br、I;
R2是氢或者与R3一起形成碳酸酯、氨基甲酸酯或碳亚甲基桥;
R3是氢或者与R2一起形成碳酸酯、氨基甲酸酯或碳亚甲基桥;
R4是直链或支链或环状C1-C6脂肪族基团、C6-C12芳基或杂芳基;
R5是直链或支链的C1-C6烷氧基羰基或直链或支链的C1-C6酰基、或芳氧基羰基。
式III化合物按照本发明的方法制备,该方法包括以下步骤:
a)将10-去乙酰基浆果赤霉素III保护为7,10-二-三氯乙酸酯;
b)与式II的衍生物或其活化的类似物缩合;
c)除去在7-和10-位的三氯乙酰基;
d)用醋酸铜氧化;
e)断裂还原;
f)除去噁唑烷。
在另一方面,本发明还提供了制备式IV化合物的方法
其中R1、R2、R3、R4和R5具有上文所定义的含义,该方法包括以下步骤:
a)将10-去乙酰基浆果赤霉素III保护为7,10-二-三氯乙酸酯;
b)与式II的衍生物或其活化的类似物缩合;
c)除去在7-和10-位的三氯乙酰基;
d)用醋酸铜氧化;
e)除去噁唑烷。
式IV化合物可以从式V化合物获得,
其中
R1、R2、R3、R4和R5具有上文所定义的含义;
R6是芳基、被一个或多个直链或支链的C1-C4烷基或烷氧基基团取代的芳基;
R7是在非酸性条件下可裂解的醇保护基团;
该方法通过以下步骤进行:
a)除去7-和10-位的保护基团;
b)用醋酸铜和氧气进行氧化;
c)除去噁唑烷。
以下中间体是新的,并且也是本发明的另一目的:
其中R1、R2、R3、R4、R5、R6、R7具有上文所述的含义,
发明详述
将10-去乙酰基浆果赤霉素III在7-和10-位进行保护并与化合物II缩合,得到如WO 01/02407中所公开的化合物。将所得偶合产物在7-和10-位脱保护,然后在氧气的存在下用催化量至化学量的在甲醇中的醋酸铜进行氧化,得到在10-位氧化的产物。所述产物可以在动力学条件下分离为7-α和7-β异构体的混合物,或者在热力学条件下分离为单一的7α异构体。由于13位羟基被酰基化,所以烯丙基过度氧化的问题得到了解决。
偶合反应以及7、10位的脱保护反应可以在单一反应器中进行,不必回收中间体。
所得产物的Norstatin链脱保护得到化合物IDN 5910,其也是用于治疗肿瘤的有发展前景的紫杉烷化合物。或者,经过断裂还原和Norstatin片段的脱保护,提供了高产率的IDN 5390。
优选地,如WO 2006/037653所述,将10-去乙酰基浆果赤霉素III保护为7,10-二-三氯乙酸酯。可以在非酸性条件下裂解的与三氯乙酰基等效的基团也可以用于并优选用于该保护反应,例如碳酸酯,如三氯乙氧基碳酸酯。
缩合反应可以在极性非质子溶剂中,在N,N-4-二甲基氨基吡啶的存在下进行。
三氯乙酰基基团使用氢氧化铵在极性非质子溶剂例如乙腈或N-甲基吡咯烷酮中,在下文所述的条件下裂解,而噁唑烷是使用催化量或化学量的酸,例如在甲醇中的盐酸,在下文进一步详细说明的条件下除去。
更具体而言,化合物IDN 5910的制备方法可以图示如下:
a)将10-去乙酰基浆果赤霉素III保护为7,10-二-三氯乙酸酯;
b)与式II的衍生物或其活化的类似物缩合;
c)除去7-和10-位的三氯乙酰基;
d)用醋酸铜氧化
e)除去噁唑烷
化合物IDN 5390的制备方法可以图示如下:
a)将10-去乙酰基浆果赤霉素III保护为7,10-二-三氯乙酸酯;
b)与式II的衍生物或其活化的类似物缩合;
c)除去7-和10-位的三氯乙酰基
d)用醋酸铜氧化
e)断裂还原
f)除去噁唑烷
上文所述方法具有普遍的有效性,其中反应机制和次序不依赖于分子上存在的任何取代基或其它官能团。
以下实施例用来更详细地说明本发明。
实施例1:10-去乙酰基浆果赤霉素III的7,10-二-三氯乙酸酯的制备
在搅拌和无水条件下将15g的10-去乙酰基浆果赤霉素III溶于60ml吡啶中。将该溶液冷却至0-5℃,并滴入6.3ml三氯乙酰氯。将该反应混合物在0℃下搅拌,直至起始原料消失(约1小时)。然后加入二氯甲烷(100mL)和4N盐酸(100mL),并保持温度低于10℃。然后分离两相,有机相用4N的HCl(100mL)再次萃取。用盐水(50mL)洗涤有机相并真空浓缩。将残余物溶于甲苯(100mL)中。搅拌该混悬液2小时,在滤器上收集沉淀并用15mL甲苯洗涤。得到24克湿产物(按HPLC滴度计算为83%,HPLC纯度为93.3%)。该产物可以直接用于后续反应或通过柱色谱进一步纯化。
1H NMR(300MHz,CDCl3,J为Hz,30(C)8.16(m,Bz),7.67(m,Bz),7.54(m,Bz),6.54(s,10),5.77(dd,10.5;7.4,H-7),5.74(d,6.9,H-2),5.03(dd,9.6;1.6,H-5),4.96(td,8.5;1.2,H-13),4.40(d,8.4,H-20a),4.22(dd,8.3,0.6,H-20b),4.06(d,6.9,H-3),2.75(ddd,14.5;9.6;7.4,H-6a),2.07(ddd,14.4;10.4;1.8,H-6b),2.38(d,8.4,H-14),2.36(s,4-OAc),2.26(d,1.4,H-18),1.95(s,H-19),1.23(s,H-17),1.15(s,H-16)。
13C NMR(75MHz,CDCl3,30(C)199.9(s,9),171.1(s,4-OCOMe),167.2(s,2-OCOPh),162.2(s,7-OCOCCl3),161.0(s,10-OCOCCl3),147.7(s,C-12),134.1(d,Bz),130.7(d,Bz),130.4(s,C-11),129.4(s,Bz),129.0(d,Bz),83.7(d,C-5),80.4(s,C-4),79.5(d,C-10),79.4(s,C-1),76.5(d,C-7),74.4(d,C-2),76.8(t,C-20),68.0(d,C-13),56.8(s,C-8),47.3(d,C-3),42.9(s,C-15),38.7(t,C-14),32.7(t,C-6),26.7(q,C-16),22.7(q,4-OCOCH3),20.3(q,C-17),15.7(q,C-18),10.9(q,C-19)。
实施例2:7,10-二-三氯乙酰基10-去乙酰基浆果赤霉素III与(4S,5R)-N-BOC-2-(2,4-二甲氧基苯基)-4-异丁基-1,3-噁唑烷-5-甲酸的缩合以及随后除去三氯乙酰基基团
将2.9克按WO 01/02407所述方法制备的IDN5401(7.2mmol,1.45当量)溶于40mL 1∶1的甲苯-水混合物中。加入5mL的10%的NaHSO4水溶液,监测到pH为约2.5。分离各层,用盐水洗涤有机层,用Na2SO4干燥,并蒸发。将残余物溶于10mL的0℃冷却的无水甲苯中,将其滴入3.70g来自实施例1的中间体(4.4mmol)在20ml甲苯中的溶液、660mg固体DMAP(5.4mmol,1.17当量)和751mg二环己基碳二亚胺(1.77当量;8.2mmol)中。将反应在0℃搅拌30分钟,然后在室温下搅拌1小时,通过TLC监测进程(硅胶,石油醚-AcOEt 7∶3,起始Rf:0.25;最终Rf:0.45)。2小时后反应完成。将该混悬液经烧结漏斗过滤。蒸发溶剂并将残余物经柱色谱(7∶3石油醚-乙酸乙酯为洗脱液)纯化得到中间体。
1H NMR(300MHz,CDCl3):δ8.05(2H,d,J=7.4Hz,or-Bz),7.61(1H,t,J=7.4Hz,p-Bz),7.46(2H,t,J=7.4Hz,m-Bz),7.22(1H,d,J=8.5Hz,Ar-6),6.59(1H,s,Ar-C(N)(OR)H),6.50(2H,br s,Ar-3+Ar-5),6.48(1H,s,H-10),6.24(1H,t,J=8.5Hz,H-13),5.76(2H,m,H-7+H-2),4.94(1H,d,J=9.8Hz,H-5),4.51(2H,m,H-2′+H-3′),4.34(1H,d,J=8.3Hz,H-20a),4.16(1H,d,J=8.3Hz,H-20b),4.00(1H,d,J=8.8Hz,H-3),3.88(3H,s,OMe),3.86(3H,s,OMe),2.29(3H,br s,H-18),1.90(3H,s,H-19),1.19,1.17(2x 3H,s,H-16+H-17),1.07(6H,m,H-6′+H-7′)。
优选不分离该中间体,而是将所得混悬液经烧结漏斗过滤,浓缩至体积约20mL,然后加入10mL甲醇和2.5mL的25%氨水溶液。在室温下搅拌该混合物,通过TLC监测进程(硅胶,石油醚-AcOEt 6∶4;起始Rf:0.6,最终Rf:0.3)。2小时后,加入30mL水对该反应进行后处理。用2N的H2SO4酸化,用AcOEt萃取。用盐水洗涤有机相,干燥(Na2SO4)并蒸发。残余物经重力柱色谱(35g硅胶,6∶4石油醚-AcOEt为洗脱液)纯化,得到2.67g产物(65%)。
1H NMR(300MHz,CDCl3):δ8.03(2H,d,J=7.4Hz,or-Bz),7.58(1H,br t,J=7.4Hz,p-Bz),7.45(2H,d,J=8.5Hz,m-Bz),7.21(1H,d,J=8.5Hz,Ar-6),6.59(1H,s,Ar-C(N)(OR)H)),6.47(2H,m,Ar-3+Ar-5),6.17(1H,t,J=8.4Hz,H-13),5.66(1H,d,J=9.3Hz,H-2),5.24(1H,s,H-10),4.93(1H,d,J=9.6Hz,H-5),4.45(2H,m,H-2′+H-7′),4.28(1H,d,J=8.1Hz,H-20a),ca.4.28(1H,m,H-3′),4.16(1H,d,J=8.1Hz,H-20b),3.95(1H,d,J=7.3Hz,H-3),3.86(3H,OMe),3.81(3H,s,OMe),2.26(3H,br s,H-18),2.12(3H,s,OAc),1.71(3H,s,H-19),1.23(9H,s,N-BOC),1.20(3H,s,H-16(17)),1.10(3H,s,H-17(16)),1.06(6H,d,J=6.0Hz,H-6′+H-7′)。
实施例3:用醋酸铜和氧气氧化
将2.0g来自实施例2的中间体(2.1mmol)溶于20ml的1∶1甲醇和DMF混合物中。然后,在剧烈搅拌下加入200mg的Cu(OAc)2.3H2O。搅拌该反应,通入含5%氧气的氮气。通过TLC监测进程(起始Rf:0.25;最终Rf:0.45)。反应完成后,将混合物经硅藻土过滤,真空蒸干甲醇。将残余物倒入水中并用乙酸乙酯(25mL)萃取。有机相用1%氨水溶液洗涤,用硫酸钠干燥并蒸发。粗产物可通过硅胶(15g)过滤纯化,用5∶5石油醚-AcOEt洗涤,得到2.26g(65%)产物,为无定形固体。
1H NMR(200MHz,CDCl3):δ8.08(d,J=7.4Hz,AA′-Bz),7.62(t,J=7.4Hz,C-Bz),7.48(t.J=7.4Hz,BB′-Bz),7.15(d,J=8.1Hz,H-18′),6.59(br s,H-7′),6.51(br d,J=8.1Hz,H-17′),6.45(br s,H-15′),6.17(br t,J=8.4Hz,H-13),5.87(d,J=9.0Hz,H-2),4.91(t,J=7.5Hz,H-7),4.72(br d,J=10Hz,H-5),ca.4.55(m,H-2′和H-3′),4.40(d,J=8.0Hz,H-20a),4.31(d,J=8.0Hz,H-20b),4.07(br s,H-7),3.80(s,OMe),2.46(dd,J=16.0和10.0Hz,H-6a),2.36(br s,18-Me),2.08(s,4-OAc),1.96(s,19-Me),1.38(s,BOC),1.28和1.21(s,H-16和H-17),1.09(d,H-6′)。
13C NMR(50MHz,CDCl3):δ207.9,188.5,172.4,171.1,171.1,167.0,161.5,159.1,152.9,142.9,141.2,133.9,130.0,129.1,128.7,104.3,96.3,82.6,81.3,80.7,79.8,79.5,76.6,75.1,71.2,58.9,57.1,55.4,43.6,40.2,39.6,36.5,35.2,28.1,27.0.26.1,25.7,23.1,22.6,21.9,21.8,15.0,14.4。
实施例4:裂解噁唑烷得到IDN 5910
将来自实施例3的产物(1g,1.07mmol)在甲醇(15mL)的溶液中加入三氟乙酸(0.060mL)并在室温下搅拌该混合物8小时。加入二氯甲烷(15mL)和水(20mL)。分离各相。水相用二氯甲烷(10mL)萃取。合并的有机相用水(10mL)洗涤并用Na2SO4干燥。蒸干溶剂并将粗产物经柱色谱(硅胶,40g,70∶30石油醚-乙酸乙酯)纯化。将包含IDN 5910的流分合并,蒸干溶剂,由此得到680mg(72%)产物,为白色固体。
1H NMR(300MHz,CDCl3,J为Hz,25(C)8.13(d,J=8.3,Bz),7.62(t,J=8.3,Bz),7.54(t,J=8.3,Bz),6.15(br t,J=9.0,H-13),5.84(d,J=7.2,H-2),4.90(br t,J=5.4,H-3′),4.64(d,J=10.0,H-5),4.45(br s,H-2′),4.41(d,J=8.8,H-20a),4.32(d,J=8.8,H-20b),4.18(br s,H-7),4.01(d,J=7.2,H-3),2.48(s,4-Ac),1.80(br s,H-18),1.72(s,H-19),1.24(s,H-15),1.21(s,H-16),0.97(d,J=6.8,H-6′),0.95(d,J=6.8,H-7′)。
IR(KBr压片):3448,1740,1708,1601,1508,1363,1258,1169,1090,1061cm-1。
13C NMR(75MHz,CDCl3,RT)207.9(s),188.6(s),172.5(s),172.0(s),166.9(s),155.7(s),143.3(s),141.0(s),133.8(d),130.2(d),129.2(s),128.7(d),82.6(d),81.6(s),79.8(s),79.1(s),77.4(t),77.1(d),75.0(d),73.0(d),71.9(d),57.1(s),51.4(d),41.0(t),40.2(s),39.4(d),36.0(t),35.2(t),30.8(d),28.1(q),25.9(q),24.7(q),23.1(q),22.6(q),22.3(q),21.9(q),14.9(q),14.2(q)。
实施例5:断裂还原
向冷却(-15℃,冰浴)的10-去乙酰基-10-脱氢-13-浆果赤霉素基(4S,5R)-N-BOC-2-(2,4-二甲氧基苯基)-4-异丁基-1,3-噁唑烷-5-甲酸酯(1.20g,1.28mmol)在无水THF(10mL)的溶液中逐滴加入1.0M的L-Selectride在THF中的溶液(3.00mL,3.00mmol,2.3当量)。在加入还原剂后立即通过TLC监测反应(硅胶,6∶4石油醚-AcOEt;起始Rf:0.45;最终Rf:0.30)。15分钟后,通过加入2N的H2SO4对该反应进行后处理。分离有机相,再用盐水洗涤,然后蒸发。残余物经重力柱色谱(12.5g硅胶,石油醚-AcOEt6∶4)纯化,得到613mg的IND 5570(51%)。
1H NMR(300MHz,CDCl3,J值Hz,30(C)8.03(d,7.4,m-Bz),7.65(t,7.4,p-Bz),7.52(t,7.4,or-Bz),7.22(d,8.6,H-18′),6.62(s,H-7′),6.56(s,H-9-OH),6.52(dd,8.6,2.5,H-17′)6.48(d,2.3,H-15′),6.17(td,8.4,1.4,H-13),5.68(d,9.4,H-2),4.67(m,H-2′),4.56(dd,8.3,4.5,H-3′),5.23(d,11.2,H-5),4.35(s-宽峰,H-3),5.31(s-宽峰,H-20),4.32(d,7.8),3.84(s,OMe),3.84(s,OMe),3.85(m,H-7),3.49(m),2.76(m,H-14),2.62(dd,16.3,9.7),2.08(d,1.2,H-18),1.85(s-宽峰,H-4′),1.69(m),1.93(s-宽峰,H-19),2.16(m,H-6),1.86(m,H-5′),1.86(s,OCOCH3),1.31(s,H-17),1.16(s,H-16),1.10(d,6.2,H-6′),1.10(d,6.1,H-6′),1.36(t-But),8.45(s,9-OH),8.02(d,7.2,m-Bz),7.69(t,7.2,p-Bz),7.53(t,7.2,or-Bz),7.15(d,8.1,H-18′),6.58(m,H-17′),6.58(m,H-15′),6.45(s,H-7′),6.06(t,8.0,H-13),5.53(d,9.2,H-2),5.05(OH),4.82(s-宽峰,H-5),4.44(t 4.6,H-3′),4.14(m,H-20),3.80(s,16′-OMe),3.77(s,14′-OMe),3.64(m,H-7),3.26(m),2.48(dd,15.7,9.0,H-14),1.89(s-宽峰,H-18),1.85(m,H-5′),1.81(s-宽峰,H-16),1.69(m,H-4′),1.27(s-宽峰,t-But),1.10(d,6.6,H-6′),1.05(d,6.6,H-6′),1.86(s,OCOCH3)。
13C NMR(75MHz,CDCl3,30℃)191.4(s,10),171.2(s,C-1′+OCOCH3),169.3(s,C-10′),167.7(s,COBz),161.9(s,C-16′),159.2(s,C-14′),153.2(s,C-13′),149.1(s,C-9),142.7(s,C-11),136.6(s,C-12),134.1(d,p-Bz),129.5(s,q-Bz),129.8(d,m-Bz),129.2(d,or-Bz),127.8(d,C-18′),125.0(s,C-8),104.8(d,C-17′),98.6(d,C-15′),87.3(d,C-7′),86.4(s,C-4),86.4(d,C-5),80.7s,8′),81.0(s,C-1),80.3(d,C-2′),74.9(d,C-2),75.0(t,C-20),71.0(d,C-13),59.2(d,C-3′),59.7(t,C-7),55.8(q,OMe),55.6(q,OMe),44.9(d,C-3),),43.8(t,C-4′),43.2(s,C-15),37.1(t,C-14),38.5(t,C-6),28.4(q,t-But),25.9(q,C-17),22.4(q,OCOCH3),25.2(d,C-5′),23.4(q,C-6′),22.3(q,C-6′),21.2(q,C-16),15.2(q,C-18),14.7(q,C-19)。
实施例6:裂解噁唑烷得到IDN 5390
将三氟乙酸(0.2mL)加入到来自实施例5的产物(4g,2.7mmol)在甲醇(12mL)的溶液中,在室温下搅拌该混合物过夜。然后加入二氯甲烷(20mL)和水(14mL)并分离各相。水相用另一部分的二氯甲烷(5mL)萃取。合并的有机相用水(2mL)洗涤并用硫酸钠干燥。将有机相经柱色谱(60g,用二氯甲烷填充的硅胶)纯化,先用二氯甲烷、然后用CH2Cl2∶95%EtOH=98∶2洗脱。将包含所需产物的流分合并,减压蒸发溶剂并将残余物溶于THF(10mL)中。在搅拌下向该溶液中加入正庚烷(10mL),放置2小时。将结晶产物过滤并在60℃下真空干燥。得到1.53g(1.94mmol,71%)的IDN 5390。
1H-NMR:(CDCl3,300MHz):8.09(d,7.4,or-Bz),7.63(t,7.5,p-Bz),7.50(t,7.5,m-Bz),6.46(s,9-OH),6.25(dt,8.8,1.2,H13),5.65(d,9.6,2H),5.29(d,11.6,H5),5.18(m,20a),4.72(d,10.0,NH),4.39(d,9.0,H3),4.34(d,9.0,20b),4.27(d,2.8,H2′),4.21(m,H3′),3.92(m,7a),3.75(dd,11.0,6.1,7b),2.86(m,14a),2.50(m,6a),2.49(dd,15.6,9.8,14b),2.14(s,H16),2.12(m,H6b),1.94(s,4-OAc),1.92(d,1.5,H18),1.90(s,H19),1.73(m,H5′),1.63(m,H4′a),1.46(m,4′b),1.33(s,Boc),1.29(s,H17),1.03(d,6.6,H6′),1.02(d,6.6,H7′)。
Claims (4)
1.制备式III化合物的方法,
其中
R1是氢或者直链或支链的C1-C4烷基、直链或支链的C1-C4烷氧基、F、Cl、Br、I;
R2是氢或者与R3一起形成碳酸酯、氨基甲酸酯或碳亚甲基桥;
R3是氢或者与R2一起形成碳酸酯、氨基甲酸酯或碳亚甲基桥;
R4是直链或支链或环状C1-C6脂肪族基团、C6-C12芳基或杂芳基;
R5是直链或支链的C1-C6烷氧基羰基或者直链或支链的C1-C6酰基、或芳氧基羰基,
该方法包括以下步骤:
a)将10-去乙酰基浆果赤霉素III保护为7,10-二-三氯乙酸酯;
b)与式II的衍生物或其活化的类似物缩合;
c)除去在7-和10-位的三氯乙酰基;
d)用醋酸铜氧化;
e)断裂还原;
f)除去噁唑烷。
2.制备式IV化合物的方法,
其中R1、R2、R3、R4和R5具有上面所定义的含义,该方法包括以下步骤:
a)将10-去乙酰基浆果赤霉素III保护为7,10-二-三氯乙酸酯;
b)与式II的衍生物或其活化的类似物缩合;
c)除去在7-和10-位的三氯乙酰基;
d)用醋酸铜氧化;
e)除去噁唑烷。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2006A002479 | 2006-12-21 | ||
IT002479A ITMI20062479A1 (it) | 2006-12-21 | 2006-12-21 | Processo per la preparazione di secotassani |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101631782A true CN101631782A (zh) | 2010-01-20 |
Family
ID=39589051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200780046778A Pending CN101631782A (zh) | 2006-12-21 | 2007-12-17 | 制备开环紫杉烷类的方法 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2091931A2 (zh) |
JP (1) | JP2010513459A (zh) |
KR (1) | KR20090092285A (zh) |
CN (1) | CN101631782A (zh) |
AU (1) | AU2007341070A1 (zh) |
CA (1) | CA2673238A1 (zh) |
IT (1) | ITMI20062479A1 (zh) |
MX (1) | MX2009006581A (zh) |
NO (1) | NO20092337L (zh) |
RU (1) | RU2009123160A (zh) |
WO (1) | WO2008081247A2 (zh) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2696458B1 (fr) * | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Procédé de préparation de dérivés du taxane. |
DE69433146T2 (de) * | 1993-06-11 | 2004-06-09 | Pharmacia & Upjohn Co., Kalamazoo | Delta 6,7-Taxol Derivate antineoplastische Verbindungen und diese enthaltende pharmazeutische Zusammenstellungen |
WO1996003394A1 (en) * | 1994-07-26 | 1996-02-08 | Indena S.P.A. | Semi-synthetic taxanes with anti-tumoural activity |
IT1308636B1 (it) * | 1999-03-02 | 2002-01-09 | Indena Spa | Procedimento per la preparazione di tassani da 10-desacetilbaccatinaiii. |
ITMI991483A1 (it) * | 1999-07-06 | 2001-01-06 | Indena Spa | Derivati tassanici e procedimenti per la loro preparazione |
US7247738B2 (en) * | 2002-05-07 | 2007-07-24 | Dabur India Limited | Method of preparation of anticancer taxanes using 3-[(substituted-2-trialkylsilyl) ethoxycarbonyl]-5-oxazolidine carboxylic acids |
US6900342B2 (en) * | 2002-05-10 | 2005-05-31 | Dabur India Limited | Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof |
-
2006
- 2006-12-21 IT IT002479A patent/ITMI20062479A1/it unknown
-
2007
- 2007-12-17 AU AU2007341070A patent/AU2007341070A1/en not_active Abandoned
- 2007-12-17 RU RU2009123160/04A patent/RU2009123160A/ru not_active Application Discontinuation
- 2007-12-17 EP EP07859076A patent/EP2091931A2/en not_active Withdrawn
- 2007-12-17 CN CN200780046778A patent/CN101631782A/zh active Pending
- 2007-12-17 WO PCT/IB2007/003951 patent/WO2008081247A2/en active Application Filing
- 2007-12-17 CA CA002673238A patent/CA2673238A1/en not_active Abandoned
- 2007-12-17 MX MX2009006581A patent/MX2009006581A/es unknown
- 2007-12-17 JP JP2009542257A patent/JP2010513459A/ja active Pending
- 2007-12-17 KR KR1020097012719A patent/KR20090092285A/ko not_active Application Discontinuation
-
2009
- 2009-06-18 NO NO20092337A patent/NO20092337L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20092337L (no) | 2009-07-14 |
AU2007341070A1 (en) | 2008-07-10 |
WO2008081247A3 (en) | 2008-10-09 |
EP2091931A2 (en) | 2009-08-26 |
WO2008081247A2 (en) | 2008-07-10 |
RU2009123160A (ru) | 2010-12-27 |
KR20090092285A (ko) | 2009-08-31 |
CA2673238A1 (en) | 2008-07-10 |
MX2009006581A (es) | 2009-06-30 |
JP2010513459A (ja) | 2010-04-30 |
ITMI20062479A1 (it) | 2008-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10238621B2 (en) | 9,10-α,α-OH-taxane analogs and methods for production thereof | |
RU2134688C1 (ru) | Полусинтетический таксан, промежуточные соединения, способы получения и фармацевтическая композиция | |
KR100378972B1 (ko) | 델타12,13-이소-탁솔유사체,항종양제용도및그를함유하는약학조성물 | |
EP2768819B1 (en) | Cabazitaxel, related compounds and methods of synthesis | |
WO1998008833A1 (en) | Sulfenamide taxane derivatives | |
NZ248295A (en) | 7-deoxy taxol derivatives; intermediates; preparation thereof and pharmaceutical compositions | |
WO2007126893A2 (en) | A convergent process for the synthesis of taxane derivatives | |
AU706155B2 (en) | 7-deoxy-6-substituted paclitaxels | |
PL174374B1 (pl) | Fluorotaksole | |
CZ302810B6 (cs) | Zpusob výroby 14beta-hydroxy-1,14-karbonátdeacetylbaccatinu III | |
CN101631782A (zh) | 制备开环紫杉烷类的方法 | |
CN103012329A (zh) | 一种制备紫杉醇类抗癌药Cabazitaxel XRP6258的方法 | |
KR100921036B1 (ko) | 탁산유도체의 제조방법 및 이에 사용되는 중간체 | |
CN103012328B (zh) | 一种制备第二代紫杉醇类抗癌药Cabazitaxel的方法 | |
CZ20031534A3 (cs) | Způsob výroby paclitaxelu | |
EP1894921A2 (en) | 9, 10-Alpha, Alpha-Oh-Taxane analogs and methods for production thereof | |
JPH08505856A (ja) | 10−デスアセトキシバッカチン▲iii▼の製法 | |
KR101402122B1 (ko) | 탁산 유도체의 제조 방법 | |
Zhang et al. | Synthesis of 7, 9-dideoxybaccatin IV analogs from sinenxan A | |
EP0747372A1 (en) | Taxane derivatives from 14-beta-hydroxy-10 deacetybaccatin III |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100120 |